Targeting the HIV-1 Spike and Co-Receptor With Bi- And Trispecific Antibodies for Single-Component Broad Inhibition of Entry

Journal of Virology - United States
doi 10.1128/jvi.00384-18
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Microbiology

Related search

Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain

2020English

Bi-Directional Heterologous Desensitization Between the Major HIV-1 Co-Receptor CXCR4 and the Κ-Opioid Receptor

Journal of Neuroimmunology
AllergyImmunologyNeurology
2008English

Competitive Exclusion by Autologous Antibodies Can Prevent Broad HIV-1 Antibodies From Arising

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2015English

CXCR7/ACKR3-targeting Ligands Interfere With X7 HIV-1 and HIV-2 Entry and Replication in Human Host Cells

Heliyon
Multidisciplinary
2018English

Striking HIV-1 Entry by Targeting HIV-1 Gp41. But, Where Should We Target?

PLoS ONE
Multidisciplinary
2016English

On the Interactions of the Receptor-Binding Domain of SARS-CoV-1 and SARS-CoV-2 Spike Proteins With Monoclonal Antibodies and the Receptor ACE2

2020English

Inhibition of the HIV-1 Spike by Single-Pg9/16-Antibody Binding Suggests a Coordinated-Activation Model for Its Three Protomeric Units

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2013English

Multifaceted Mechanisms of HIV-1 Entry Inhibition by Human Α-Defensin

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2012English

Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis

Current Topics in Medicinal Chemistry
MedicineDrug Discovery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy